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Globally 166 000 women die annually as a result of obstetric 
haemorrhage. More than 50% of these deaths occur in sub-Saharan 
Africa. Uterine atony is the commonest cause of severe postpartum 
haemorrhage (PPH).[1] The term ‘significant obstetric haemorrhage’, 
defining a loss of >1 500 mL, can also be used to describe PPH.[2]
The preliminary data of the 2011 - 2013 Saving Mothers triennial 
report[3] revealed that obstetric haemorrhage accounted for 684 
maternal deaths, making it the second most common cause of 
maternal death in South Africa (SA). One of the major concerns was 
bleeding after caesarean section (CS). The following major causes 
have been identified among the cohort of the 2011 - 2013 deaths 
ascribed to haemorrhage:[3] (i) inadequate utilisation of uterotonic 
agents; (ii) poor recognition of the severity of the blood loss causing 
hypovolaemia; (iii) inadequate surgical skill; and (iv) delays in 
relaparotomy and/or referral in case of post-CS bleeding.
Oxytocin (Syntocinon; Sandoz) can be administered in several 
different ways during CS to prevent PPH. At Kalafong Provincial 
Tertiary Hospital (KPTH), Pretoria, SA, oxytocin 2.5 IU is given as an 
intravenous bolus followed by 7.5 IU in the remaining Vaculiter to be 
administered during the CS. According to the Green Top Guidelines 
No. 52 of the Royal College of Obstetrics and Gynaecology,[4] the 
required initial bolus dose is 5 IU slowly as an intravenous infusion 
(IVI). There has also been a recent publication that referred to the 
‘rule of threes’ as a means of administering oxytocin: 3 IU IVI as 
a slow bolus every 3 minutes depending on the contraction of the 
uterus.[5] The following guidelines were published in the SAMJ in 
April 2015 for primary prophylaxis of PPH at CS:[6] (i) oxytocin 
2.5  IU IVI as a slow bolus (over 30 seconds); (ii) oxytocin 7.5 IU 
in the remaining IVI fluid running in; and (iii) oxytocin infusion 
20 IU/1 000 mL at 125 mL/h for 8 hours (125 mL/h is equivalent to 
42 drops per minute from a ‘20 dropper’ administration set).
One of the key recommendations from the Saving Mothers 
report 2008 - 2010[7] is to use the combination of oxytocin + 
ergometrine (Syntometrine; Sandoz) as the second-line treatment for 
uterine atony in preference to misoprostol, unless contraindicated. 
In addition, this combination is to be considered at CS as primary 
prophylaxis for PPH.[7]
Oxytocin + ergometrine has mainly been reserved as a second-
line agent in the management of PPH at the time of CS. In view 
of the unacceptable number of maternal deaths due to obstetric 
haemorrhage following CS, it is important to investigate the use of 
alternative measures to prevent PPH at CS.
Objective
To compare the efficacy of oxytocin + ergometrine with that of 
oxytocin in the primary prevention of PPH at CS.
Methods
This was a double-blind placebo-controlled randomised study 
done at KPTH. All pregnant women aged ≥18 years undergoing 
elective or emergency lower-segment CS, who were able to provide 
informed consent and did not have any of the exclusion criteria 
listed in Table 1, were eligible for recruitment to the study.
Pre- and postoperative measurement of the haematocrit and 
intra operative estimated visual blood loss were used as indicators of 
blood loss. A questionnaire was used postoperatively to assess the 
side-effects experienced by patients recruited to the study. The need 
for blood transfusion and additional medication was also recorded.
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Background. Globally 166 000 women die annually as a result of obstetric haemorrhage. More than 50% of these deaths occur in sub-
Saharan Africa. Uterine atony is the commonest cause of severe postpartum haemorrhage (PPH). Bleeding at or after caesarean section (CS) 
is responsible for >30% of maternal deaths due to obstetric haemorrhage in South Africa (SA).
Objective. To compare oxytocin alone with oxytocin + ergometrine in terms of primary prophylaxis for PPH at the time of CS.
Methods. This was a double-blind randomised controlled interventional study comparing oxytocin with oxytocin + ergometrine admini-
stered during CS. Patients were randomised to receive oxytocin alone intravenously as a bolus or oxytocin + ergometrine intramuscularly, 
with the placebo being an injection of sterile water. The study population consisted of women undergoing CS at Kalafong Provincial Tertiary 
Hospital in Atteridgeville, Gauteng, SA.
Results. Five hundred and forty women were randomised and data for 416 women, of whom 214 received oxytocin and 202 oxytocin + 
ergometrine, were available for analysis. In the oxytocin group 19 women (8.9%) required blood transfusion, compared with seven (3.5%) 
in the oxytocin + ergometrine group (p=0.01; relative risk = 2.78; 95% confidence interval 1.21 - 6.4). There were no statistically significant 
differences in the mean estimated visual and mean calculated blood loss.
Conclusions. The overall need for blood transfusion was significantly reduced by about two-thirds in women receiving the oxytocin + 
ergometrine combination. Consideration should be given to using oxytocin + ergometrine for prophylaxis of PPH at CS.
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Patients were randomised to receive either 
2.5 U oxytocin alone intravenously as a bolus 
and placebo intramuscularly, or 5 U oxy-
tocin + 0.5 mg ergometrine (1 ampoule of 
Syntometrine) intramuscularly and placebo 
intravenously, after delivery of the neonate. 
In both groups an additional 10 U of oxytocin 
were added to the Vaculiter. The anaesthetists 
involved in the respective cases administered 
all drugs. Recruitment took place from 
2 Janu ary 2014 until I June 2014, only when 
the research co-ordinator was on site.
Randomisation was by means of sealed non-
transparent envelopes. Each had a label inside 
with a letter A (oxytocin group) or B (oxytocin 
+ ergometrine), which corresponded to a pair 
of prepacked colour-coded ampoules that 
were used for the two different groups. Each 
pair of ampoules consisted of one ampoule 
with an active ingredient (oxytocin 2.5 IU 
alone or oxytocin 5 IU + ergometrine 0.5 
mg), as well as a placebo ampoule containing 
sterile water for injection. The glass ampoules 
were covered in red and blue coloured tape to 
disguise the ingredients. The blue ampoules 
were administered intravenously and the 
red ampoules intramuscularly. Following 
randomisation into one of the two groups, 
the appropriate prepacked ampoules were 
handed to the anaesthetist for administration. 
The anaesthetists, obstetricians and study 
participants were all blinded as to what active 
ingredients were administered.
In the event of PPH, treatment was per the 
standard protocol and guidelines. The active 
ingredient used to prevent PPH did not 
influence its treatment.
The sample size was calculated making 
use of a control value of severe PPH of 22%,[3] 
an absolute difference between control and 
intervention of 10% reduction in bleeding 
at CS suggesting that the intervention was 
effective. The resulting sample size was 221 
women in each group.
Preoperative and postoperative (6 - 24 
hours) haematocrit or haemoglobin values 
were measured. In some cases arterial blood 
gas haemoglobin levels were used. In addition, 
visual estimated blood loss was documented. 
Calculation of blood loss was done using 
calculated pregnancy preoperative blood 
volume (0.75 × [{height inches × 50} + {weight 
pounds × 25}) × percentage of blood volume 
lost ([pre-delivery haematocrits – post-delivery 
haematocrits]/pre-delivery haematocrits), as 
described by Stratford et al.[8]
The need for additional uterotonics and 
the number of units of blood transfused 
were documented. The anaesthetist and 
obstetrician managing the individual patients 
made the decision for blood transfusion 
based on clinical assessment at the time of CS.
Data were entered into an Excel database for 
checking and editing. This was then impor ted 
into SPSS version 21 for analysis. Descriptive 
statistics were used to describe the population 
as a whole. Comparisons between patients 
receiving the intervention and the control 
group were made using independent-sample 
t-tests in the case of continuous data and χ2 
tests in the case of categorical data.
The study was approved by the Research 
Ethics Committee, Faculty of Health 
Sciences, University of Pretoria (391/2013), 
and was registered on ClinicalTrials.gov 
(NCT02046499).
Results
Five hundred and forty women were random-
ised to the study (Fig. 1). Data on 124 patients 
who were randomised were excluded from 
analysis. Of these, 80 delivered vaginally 
and another 44 were excluded because of 
incomplete data or protocol violations, 
resulting in data on 416 women that were 
analysed. Two hundred and fourteen women 
were randomised to receive oxytocin alone 
and 202 received oxytocin + ergometrine.
The two groups of patients were analysed in 
terms of age, parity, gravidity and gestational 
ages in weeks. The results are shown in Table 2.
Table 1. Exclusion criteria
Women not willing or not able to provide 
consent
Women who have had a classic CS
Women <18 years of age
Women with any of the following 
conditions (ergometrine contraindicated in 
patients with these conditions):
Pre-eclampsia
Eclampsia
 Uncontrolled hypertension 
(hypertension defined as systolic blood 
pressure >140 mmHg and diastolic 
blood pressure >90 mmHg)
Any cardiac lesion
Impaired liver function
Impaired kidney function
 Hypersensitivity to any of the active 
ingredients of the preparations that 
will be used (oxytocin or oxytocin + 
ergometrine)
Occlusive vascular disease
Autoimmune vasculitis
Table 2. Demographic data
O group
(n=214), mean (SD) 
O+E group 
(n=202), mean (SD) p-value
Age (years) 28.6 (6.0) 28.9 (5.4) 0.59
Parity (n) 1.2 (1.1) 1.1 (0.9) 0.21
Gravidity (n) 2.4 (1.3) 2.4 (1.1) 0.44
Gestational age 
(weeks)
38.4 (2.2) 38.5 (1.9) 0.33
Height (cm) 159.4 (15.2) 160.2 (11.3) 0.57
Weight (kg) 75.6 (16.2) 76.6 (17.2) 0.53
MUAC (cm) 29.6 (3.8) 30.1 (4.6) 0.26
O = oxytocin; O+E = oxytocin + ergometrine; SD = standard deviation; MUAC = mid-upper arm circumference.
Table 3. Indications for CS
Indication for CS
O group  
(N=214), n (%)
O+E group  
(N=202), n (%)
Total  
(N=416), n (%)
Previous CS 91 (42.5) 97 (48.0) 188 (45.2)
Fetal distress 49 (22.9) 38 (18.8) 87 (20.9)
Cephalopelvic disproportion 19 (8.9) 22 (10.9) 41 (9.9)
Poor progress 17 (7.9) 13 (6.4) 30 (7.2)
Failed induction of labour 6 (2.8) 8 (4.0) 14 (3.4)
Breech 9 (4.2) 5 (2.5) 14 (3.4)
Twins 5 (2.3) 6 (3.0) 11 (2.6)
Other 13 (8.4) 11 (6.4) 24 (7.4)
O = oxytocin; O+E = oxytocin + ergometrine.
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The most common indication for per-
form ing CS in the study population was a 
previous CS (n=188, 45.2%). The indications 
for CS are listed in Table 3.
Women who underwent emergency CS 
were compared with those who had elective 
CS, and these results are shown in Table 
4. Two hundred and sixty-seven women 
(64.2%) underwent emergency CS and 149 
(35.8%) had elective CS.
Three hundred and ninety-three 
patients (94.5%) were administered a 
spinal anaesthetic and 23 (5.5%) a general 
anaesthetic. There were no statistically 
significant differences between the two 
groups (p=0.721). Spinal anaesthesia was 
administered to 203 patients (94.9%) in the 
oxytocin group and to 190 (94.1%) in the 
oxytocin + ergometrine group.
The mean estimated visual blood loss in 
the oxytocin group was 607 mL and that in 
the oxytocin + ergometrine group 588 mL 
(p=0.437).
Women who received intraoperative or 
immediate postoperative blood transfusions 
were excluded from the postoperative calcu-
lated blood loss analysis. Data on 371 of the 
417 patients analysed were used for calculated 
blood loss. The preoperative values were not 
statisti cally different between the two groups 
(p=0.707) and the postoperative haema-
to crit values also did not differ (p=0.283). 
The oxytocin group had a mean post-
operative haematocrit of 0.324, while the mean 
postoperative haematocrit in the oxytocin  + 
ergometrine group was 0.329. The mean 
calculated blood loss in the oxytocin group was 
610 mL (95% confidence interval (CI) 0.321 - 
0.335) and that in the oxytocin + ergometrine 
group 590 mL (95% CI 0.326 - 0.338) (p=0.445).
The need for blood transfusion was 
calculated using χ2 tests. Nineteen women 
(8.9%) in the oxytocin group required a blood 
transfusion as opposed to seven (3.5%) in 
the oxytocin + ergometrine group (p=0.01; 
relative risk (RR) 2.78; 95% CI 1.21 - 6.4)
The need for additional uterotonics was 
also recorded. In total, these were required by 
36 patients (8.7%), 16 (7.5%) in the oxytocin 
group and 20 (9.9%) in the oxytocin + 
ergometrine group. This difference was not 
significant (p=0.379).
Two hundred and four women in the 
oxy tocin group (95.3%) experienced no 
bothersome side-effects, compared with 194 
(96.0%) in the oxytocin + ergometrine group 
(p=0.81).
Discussion
Data from the latest Saving Mothers report[3] 
suggest that maternal morbidity and mortality 
secondary to obstetric haemorrhage at CS is 
on an upward trend. It is useful to note that if 
the risk of death from vaginal delivery is 1, the 
relative risk for all CSs is 4.9. The relative risk for 
elective CS is 2.3 compared with 12.0 when the 
caesarean is performed because of immediate 
threat to the life of the mother or fetus.[9] 
For this reason, administration of uterotonic 
drugs during CS has become of paramount 
importance in prophylaxis as a strategy for 
improving maternal morbidity and mortality.[10]
Total caesarean
sections during the
study period
N=1 020
Excluded
n=690
Randomised and
eligible
n=540
Not eligible,
exclusion
criteria met
n=210
Researcher not
on site
n=480
Patients analysed
n=416
Oxytocin group
n=214
Oxytocin +
ergometrine group
n=202
Vaginal delivery
while waiting
for theatre
n=80
Incomplete data
n=44
Fig. 1. Flow diagram of randomised patients.
Table 6. Comparison of blood loss in the oxytocin v. oxytocin + ergometrine groups and need for blood transfusion
Preoperative 
haematocrit, 
mean (SD)
Postoperative 
haematocrit,  
mean (SD)
Estimated visual 
blood loss (mL), 
mean (SD)
Calculated blood 
loss (mL),  
mean (SD)
Need for blood 
transfusion, n (%)
O group (n=214) 0.358 (0.045) 0.324 (0.05) 607 (246) 610 (249) 19 (8.9)
O+E group (n=202) 0.359 (0.045) 0.329 (0.045) 588 (236) 590 (245) 7 (3.5)
O = oxytocin; O+E = oxytocin + ergometrine; SD = standard deviation.
Table 5. Comparison of side-effects
Side-effect
O group 
(n=214), n (%)
O+E group 
(n=202), n (%) p-value
Nausea 23 (11.7) 26 (12.9) 0.722
Vomiting 5 (2.3) 11 (5.4) 0.092
Headache 20 (9.3) 20 (9.9) 0.065
Palpitations 9 (4.2) 17 (8.4) 0.294
Dizziness 29 (13.6) 28 (13.9) 0.867
O = oxytocin; O+E = oxytocin + ergometrine.
Table 4. Comparison of emergency v. elective CSs
O group  
(N=214), n (%)
O+E group  
(N=202), n (%)
Total  
(N=416), n (%)
Emergency CS 136 (63.6) 131 (64.9) 267 (64.2)
Elective CS 78 (36.4) 71 (35.1) 149 (35.8)
O = oxytocin; O+E = oxytocin + ergometrine.
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Other data comparing oxytocin alone with the combination 
of ergometrine + oxytocin have shown a small but statistically 
significant reduction in the risk of PPH (odds ratio (OR) 0.82; 
95% CI  0.71 - 0.95), with no difference in the risk of severe PPH. 
Ergo metrine + oxytocin was also associated with a reduced need 
for additional uterotonic drugs (OR 0.83; 95% CI 0.72 - 0.96), with 
no difference in the risk of manual removal of the placenta.[7] Four 
randomised trials compared different uterotonics for prophylaxis 
of PPH in women delivering by CS. In the UK, appraisal of these 
trials together with consideration of standard practice led to the 
development group for the National Institute for Health and Clinical 
Excellence (NICE) Caesarean Section Guideline.[10]
Results from this study showed no significant differences in 
terms of calculated or visual blood loss using oxytocin or oxy-
tocin + ergometrine for prophylaxis of PPH at the time of CS. The 
oxytocin group had a non-significant trend towards a slightly higher 
calculated and visual blood loss. The most important finding of 
this study is that the need for blood transfusions (based on clinical 
indications) was significantly higher in the oxytocin group than in 
the oxytocin + ergometrine group (p=0.01). Women in the oxytocin 
group were more than twice as likely to require a blood transfusion 
as those in the oxytocin + ergometrine group (RR 2.78; 95% CI 1.21 - 
6.4). A possible explanation for the similar estimated and calculated 
blood loss in the two groups is that the patients who received 
blood transfusions were excluded from both groups because their 
laboratory values were not sufficiently accurate for determination 
of calculated blood loss. The fact that there was no statistically 
significant difference between estimated and visual blood loss also 
suggests that the blood transfusions in the oxytocin-alone group 
were clinically indicated. There was no predefined haemoglobin or 
haematocrit concentration indicating blood transfusions, and the 
decision for transfusion was based on the treating obstetricians’ and 
anaesthetists’ clinical judgement in conjunction with haemoglobin 
concentrations and other appropriate clinical parameters, as is done 
in normal clinical practice.
There were no statistically significant differences in side-effects 
experienced between the two groups.
Conclusions
In an effort to reduce PPH at the time of CS, changing protocol from 
the use of oxytocin to oxytocin + ergometrine could influence overall 
maternal morbidity and mortality. The reduction in the need for 
blood transfusion by more than half in the oxytocin + ergometrine 
group is an important finding of this study.
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